Search Results - "Alés, I."

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients by Toledano-Fonseca, M., Gómez-España, M.A., Élez, E., Grávalos, C., García-Alfonso, P., Rodríguez, R., Losa, F., Alés Díaz, I., Graña, B., Valladares-Ayerbes, M., García-Ortiz, M.V., Polo, E., Salgado, M., Rivera, F., Safont, M.J., Salud, A., Ruiz-Casado, A., Tabernero, J.M., Riesco, M.C., Rodríguez-Ariza, A., Aranda, E.

“…The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an…”
Get full text

Management of hyperbilirubinaemia in pancreatic cancer patients by Álvarez, R., Carrato, A., Adeva, J., Alés, I., Prados, S., Valladares, M., Macarulla, T., Muñoz, A., Hidalgo, M.

“…Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For…”
Get full text

Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma by Álvarez, R., Alés, I., Díaz, R., de Paredes, B. G., Hidalgo, M.

“…Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic…”
Get full text

Analysis of patient screening in the phase III, international, randomized, open-label APACT trial by Reni, M., Winter, J., Tortora, G., Pelzer, U., Riess, H., Chang, H., O’Reilly, E., Oh, D., Diaz, I. Alés, Milella, M., Bendell, J., Garlipp, B., Tempero, M., Macarulla, T., Van Cutsem, E., Berlin, J., Goldstein, D., Lu, B., Jeanes, J., Philip, P.

Get full text

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain by Hidalgo, M., Álvarez, R., Gallego, J., Guillén-Ponce, C., Laquente, B., Macarulla, T., Muñoz, A., Salgado, M., Vera, R., Adeva, J., Alés, I., Arévalo, S., Blázquez, J., Calsina, A., Carmona, A., de Madaria, E., Díaz, R., Díez, L., Fernández, T., de Paredes, B. G., Gallardo, M. E., González, I., Hernando, O., Jiménez, P., López, A., López, C., López-Ríos, F., Martín, E., Martínez, J., Martínez, A., Montans, J., Pazo, R., Plaza, J. C., Peiró, I., Reina, J. J., Sanjuanbenito, A., Yaya, R., Carrato, Alfredo

“…The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to…”
Get full text

Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer by Benavides, M., Alcaide-Garcia, J., Torres, E., Gil-Calle, S., Sevilla, I., Wolman, R., Durán, G., Álvarez, M., Reyna-Fortes, C., Ales, I., Pereda, T., Robles, M., Kushnir, M., Odegaard, J., Faull, I., Alba, E.

“…Comprehensive biomarker testing is essential in selecting optimal treatment for patients with metastatic colorectal cancer (mCRC); however, incomplete…”
Get full text

2304 Polychemotherapy on patients with pancreatic carcinoma: Experience of four hospitals in Spain by Muriel Lopez, C, Perez-Ruiz, E, Gonzalez, I, Ales, I, Pascual, J, Duran, G, Rivas-Ruiz, F, Benavides, M, Marquez, A, Pajares, B, Plata, Y, Diaz, T, Zarcos, I, Alcaide, J, Gimenez, F.J, Lopez, P, Gil, S, Muros, B, Rueda, A, Alba, E

Get full text

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer by Benavides, M., Abad, A., Ales, I., Carrato, A., Díaz Rubio, E., Gallego, J., García-Foncillas, J., Grávalos, C., Laquente, B., Pericay, C., Rivera, F., Tabernero, J., Aranda, E.

“…Exocrine pancreatic cancer (PC) is a very aggressive and heterogeneous tumor with several cellular signaling pathways implicated in its pathogenesis and…”
Get full text

PD-001Analysis of patient screening in the phase III, international, randomized, open-label APACT trial by Reni, M, Winter, J, Tortora, G, Pelzer, U, Riess, H, Chang, H, O’Reilly, E, Oh, D, Diaz, I Alés, Milella, M, Bendell, J, Garlipp, B, Tempero, M, Macarulla, T, Van Cutsem, E, Berlin, J, Goldstein, D, Lu, B, Jeanes, J, Philip, P

Get full text

Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification by Cortés-Funes, H., Rivera, F., Alés, I., Márquez, A., Velasco, A., Colomer, R., García-Carbonero, R., Sastre, J., Guerra, J., Grávalos, C.

“…Abstract only 4613 Background: Trastuzumab(T) exhibits activity in human gastric cancer cells that overexpress HER2/neu. We previously reported a 13.5%…”
Get full text

A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC) by Hidalgo, M., Pazo-Cid, R., Guillen-Ponce, C., López, R., Vera, R., Reboredo, M., Muñoz, A., Martinez de Castro, E., Díaz Beveridge, R., La Casta, A., Martin-Valades, J.I., Cubillo, A., Martínez-Galán, J., Ales, I., Sastre, J., Macarulla Mercade, T.

Get full text

Most prevalent diseases at the end of life in elderly attended at home by Ales Siles, I, Ramírez Rodríguez, G, Gambini Muro, G, Rangel Selvera, O.A, Sánchez del Corral Usaola, F, Ruipérez Cantera, I

Get full text

Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer by Cobo, M, Delgado, R, Gil, S, Herruzo, I, Baena, V, Carabante, F, Moreno, P, Ruiz, J L, Bretón, J J, Del Rosal, J M, Fuentes, C, García, E, Villar, E, Contreras, J, Alés, I, Benavides, M

“…Organ preservation has been investigated in patients (p) with infiltrating transitional cell carcinoma (TCC) of the bladder over the past decade as an…”
Get full text

Impact of geriatric syndromes in terminal elderly attended at home by Ramírez Rodríguez, G, Ales Siles, I, Tenorio Carmona, B, Rangel Selvera, O.A, Sanchez Del Corral Usaola, F, Ruiperez Cantera, I

Get full text

Associated symptoms to terminality in elderly patient and the necessity of subcutaneous application at the home care assistance by Tenorio Carmona, B, Ramírez Rodríguez, G, Rangel Selvera, O.A, Ales Siles, I, Sanchez Del Corral Usaola, F, Ruiperez Cantera, I

Get full text

Needs of the health care in elderly terminals at home by Ales Siles, I, Rangel Selvera, O.A, Ramirez Rodriguez, G, Tenorio Carmona, B, Sanchez Del Corral Usaola, F, Ruiperez Cantera, I

Get full text

Elderly terminal patient profile attended by a geriatric home care group by Rangel Selvera, O.A, Tenorio Carmona, B, Ales Siles, I, Ramírez Rodríguez, G, Sanchez Del Corral Usaola, F, Ruiperez Cantera, I

Get full text

Elderly terminal patient profile attended by a geriatric home care group by Rangel Selvera, O.A, Tenorio Carmona, B, Ales Siles, I, Ramirez Rodriguez, G, González Esparza, S.A, Sanchez Del Corral Usaola, F, Ruiperez Cantera, I

Get full text

Primary signet-ring cell adenocarcinoma of the urinary bladder: a case report by Cobo-Dols, M., Alcaide, J., Gutiérrez, V., Gil, S., Alés, I., Villar, E., Montesa, A., Carabantes, F., Bretón, J. J., Benavides, M.

“…Primary signet-ring cell adenocarcinoma of the urinary bladder is a rare tumor. We report in this study the case of a 53 year old man consulting for gross…”
Get full text

Epigenetics Differences between Estrogen Receptor (ERS1) and Her2/Neu Status in Breast Cancer Patients by Martínez-Galán, J., Torres-Torres, B., Ales, I., Durán, G., Gutierrez, V., Del Moral, R., Cobo, M., Nuñez, M., Benavides, M., Ruiz De Almodóvar, M.

“…Abstract Background: The CpG island methylator phenotype is associated with distinct clinicophatological characteristics as Estrogen Receptor (ESR1) positive…”
Get full text